Aspira Women's Health Inc. (AWH) Social Stream

Featured Post From StockTwits About AWH

$AWH Part 2 - Eventually however, OVA1 will become standard of care and replace CA-125 – not only as a test for malignancy, but also as a monitoring test which means 1m+ tests in the US alone. The paper they just published provides clear evidence their test is better and the disparity data provides an urgency for change. Then we have ENDO – which is an even bigger opportunity. The FDA is working with Aspira because endometriosis is a horrible and undiagnosed disease that is very common among women. ABBV just adds credibility.

It’s only a matter of time until OVA and ENDO both take off and this stock turns into another EXAS or JAZZ. The shorts will be lucky if AWH is bought for $2bn (or $20/shr) because it will likely be a $50+ stock in the next few years. HODL.